An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis
Marie‐Eve Robinson(University of Ottawa), Leanne M. Ward(Children's Hospital of Eastern Ontario), Jacob L. Jaremko(University of Alberta), Lynn MacLeay, Marika Pagé, Victor N. Konji, Karine Khatchadourian, David Saleh(Boehringer Ingelheim (Germany)), Nazih Shenouda, Kerry Siminoski, Stefan A. Jackowski, Matzinger Mary Ann, Jinhui Ma(McMaster University), Nasrin Khan, Caroline Zuijdwijk
Cited by 0
Related Papers
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
|The Lancet|2019|375
Bone Strength: The Whole Is Greater Than the Sum of Its Parts
|Seminars in Arthritis and Rheumatism|2006|168
Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study
|Arthritis Care & Research|2011|144
Management of corticosteroid-induced osteoporosis
|Seminars in Arthritis and Rheumatism|2000|141